U.S. Topical Pain Relief Market by Therapeutic Class (Non-Opioids and Opioids), Formulation (Cream, Gel, Spray, Patch, and Others), Type (Prescription Pain Relief and Over-the-Counter Pain Relief), and Distribution Channel (Pharmacies & Drug Stores, E-Commerce, and Retail & Grocery Stores)- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on U.S. Topical Pain Relief Market 

5.1. COVID-19 Landscape: U.S. Topical Pain Relief Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. U.S. Topical Pain Relief Market, By Therapeutic Class

8.1. U.S. Topical Pain Relief Market, by Therapeutic Class, 2023-2032

8.1.1. Non-opioids

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Opioids

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. U.S. Topical Pain Relief Market, By Formulation

9.1. U.S. Topical Pain Relief Market, by Formulation, 2023-2032

9.1.1. Cream

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Gel

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Spray

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Patch

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 10. U.S. Topical Pain Relief Market, By Type 

10.1. U.S. Topical Pain Relief Market, by Type, 2023-2032

10.1.1. Prescription Pain Relief

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Over-the-counter (OTC) Pain Relief

10.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 11. U.S. Topical Pain Relief Market, By Distribution Channel 

11.1. U.S. Topical Pain Relief Market, by Distribution Channel, 2023-2032

11.1.1. Pharmacy & Drug Store

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. E-Commerce

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Retail & Grocery Store

11.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 12. U.S. Topical Pain Relief Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Therapeutic Class (2020-2032)

12.1.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.1.3. Market Revenue and Forecast, by Type (2020-2032)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Therapeutic Class (2020-2032)

12.1.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.1.5.3. Market Revenue and Forecast, by Type (2020-2032)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

Chapter 13. Company Profiles

13.1. ADVACARE PHARMA

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. GLAXOSMITHKLINE PLC (GSK)

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. JOHNSON & JOHNSON

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. NESTLÉ S.A.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. NOVARTIS AG

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. PFIZER INC.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. RECKITT BENCKISER GROUP PLC

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. SANOFI

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. SUN PHARMACEUTICAL INDUSTRIES LTD.,

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. TOPICAL BIOMEDICS, INC.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms